Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 4/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.32 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.32 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.32 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.32 |
| ▸ | CYP2F1 | P24903 | 2/20 | 0.32 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948399 | 0.86 | DYRK1A (0.40) | CYP1A1CYP1B1KDM4ECYP1A2CYP2E1 | |
| SCHEMBL2950392 | 0.83 | KDM4E (0.36) | ALDH1A1KDM4ECYP3A4CCNB2CDK1 | |
| SCHEMBL2951402 | 0.79 | PDE4A (0.36) | ALDH1A1KDM4E | |
| SCHEMBL6804334 | 0.78 | CYP1A1 (0.33) | CYP1A1CYP1B1ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL9429848 | 0.77 | MAPT (0.36) | ALDH1A1KDM4E | |
| SCHEMBL5576185 | 0.76 | POLB (0.40) | ALDH1A1KDM4EFGFR1 | |
| SCHEMBL5319098 | 0.74 | — | — | |
| SCHEMBL473159 | 0.73 | MAOA (0.32) | — | |
| SCHEMBL11331090 | 0.72 | MAOA (0.31) | — | |
| SCHEMBL1275382 | 0.72 | MAOA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112663086-A | Ni-N-C monatomic catalyst and preparation method and application thereof | 中科院过程工程研究所南京绿色制造产业创新研究院 | 2021-04-16 | — | — | CN | claimed |
| CN-116465945-A | Ion-selective membrane, ion-selective electrode, ion sensor, sample testing device, and complex compound | 佳能株式会社 | 2023-07-21 | — | — | CN | disclosed |
| CN-112004845-B | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate, and semiconductor device | 三菱瓦斯化学株式会社 | 2022-05-31 | — | — | CN | disclosed |
| CN-112088192-B | Color material dispersion liquid, composition, film, optical filter, and display device | 大日本印刷株式会社 | 2022-05-13 | — | — | CN | disclosed |
| CN-112663086-A | Ni-N-C monatomic catalyst and preparation method and application thereof | 中科院过程工程研究所南京绿色制造产业创新研究院 | 2021-04-16 | — | — | CN | disclosed |
| CN-112088192-A | Color material dispersion liquid, composition, film, optical filter, and display device | 大日本印刷株式会社 | 2020-12-15 | — | — | CN | disclosed |
| CN-112004845-A | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer, and semiconductor device | 三菱瓦斯化学株式会社 | 2020-11-27 | — | — | CN | disclosed |
| EP-2379109-B1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | BAUSCH HEALTH COMPANIES INC (CA) | 2020-10-07 | — | — | EP | disclosed |
| US-10696863-B2 | Additives for curable liquid compositions | DURA CHEMICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10632096-B2 | Method of quenching singlet and triplet excited states of photodegradable pigments, such as porphyrin compounds, particularly protoporphyrin IX, with conjugated fused tricyclic compounds having electron withdrawing groups, to reduce generation of singlet oxygen | HallStar Beauty and Personal Care Innovations Company (US) | 2020-04-28 | — | — | US | disclosed |
| US-20030099596-A1 | Treatment of macular edema | BAUSCH HEALTH IRELAND LIMITED (IE) | 2003-05-29 | — | — | US | disclosed |
| US-20030087889-A1 | Photodynamic therapy of occult age-related macular degeneration | BAUSCH HEALTH COMPANIES INC. (CA) | 2003-05-08 | — | — | US | disclosed |
| US-20030083649-A1 | Method for reducing or preventing PDT related inflammation | VALEANT SP. Z.O.O. (PL) | 2003-05-01 | — | — | US | disclosed |
| WO-2003028628-A2 | PHOTOSENSITIZING CARBAMATE DERIVATIVES | MIRAVANT PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
| US-20020183302-A1 | Method to prevent vision loss | TECHNOLAS PERFECT VISION GMBH (DE) | 2002-12-05 | — | — | US | disclosed |
| US-20020173832-A1 | Reduced fluence rate PDT | TECHNOLAS PERFECT VISION GMBH (DE) | 2002-11-21 | — | — | US | disclosed |
| US-20020156062-A1 | Drug delivery system for hydrophobic drugs | BAUSCH HEALTH COMPANIES INC. (CA) | 2002-10-24 | — | — | US | disclosed |
| US-20020155089-A1 | Drug delivery systems for photodynamic therapy | UNIVERSITY OF BRITISH COLUMBIA, THE (CA) | 2002-10-24 | — | — | US | disclosed |
| US-20020061330-A1 | Supports for photosensitizer formulations | BRITISH COLUMBIA, THE UNIVERSITY OF (CA) | 2002-05-23 | — | — | US | disclosed |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | QLT INC. (CA) | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030099596-A1 | Treatment of macular edema | VEGFA, PPOX, FLT4 | CYP1A1 3855/4885CYP1B1 1500/4885ALDH1A1 3216/4885 |
| US-20020183302-A1 | Method to prevent vision loss | VEGFA, ALDH1A2, PDE6C | CYP1A1 4648/4885CYP1B1 3317/4885ALDH1A1 901/4885 |
| US-10632096-B2 | Method of quenching singlet and triplet excited states of photodegradable pigments, such as porphyrin compounds, particularly protoporphyrin IX, with conjugated fused tricyclic compounds having electron withdrawing groups, to reduce generation of singlet oxygen | CBR3, NOX3, CCND3 | CYP1A1 861/4885CYP1B1 822/4885ALDH1A1 3304/4885 |
| US-20020156062-A1 | Drug delivery system for hydrophobic drugs | LIPA, MLEC, ABCG2 | CYP1A1 2331/4885CYP1B1 2812/4885ALDH1A1 2604/4885 |
| US-20020155089-A1 | Drug delivery systems for photodynamic therapy | PIN1, PPOX, DHFR | CYP1A1 429/4885CYP1B1 173/4885ALDH1A1 701/4885 |
| US-20020061330-A1 | Supports for photosensitizer formulations | PPOX, PPIF, SDHA | CYP1A1 1661/4885CYP1B1 1326/4885ALDH1A1 371/4885 |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | CD74, ANXA11, ANXA1 | CYP1A1 3153/4885CYP1B1 3529/4885ALDH1A1 794/4885 |
| US-20030087889-A1 | Photodynamic therapy of occult age-related macular degeneration | ALDH1A2, AGER, CRY2 | CYP1A1 4057/4885CYP1B1 2822/4885ALDH1A1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.